229 results about "Inflammatory cell infiltration" patented technology

The effect of anti-IL-6 receptor antibodies in suppressing cytotoxic T cell induction was examined. The results showed that CTL activity against alloantigens was statistically significantly reduced in mice treated with anti-IL-6 receptor antibodies as compared to mice not treated with antibodies and mice treated with a control antibody. The anti-IL-6 receptor antibody was also administered to recipients of a mouse model for allogenic heart transplantation. As a result, histopathological findings showed that inflammatory cell infiltration into transplanted hearts was suppressed and the survival period of transplanted hearts was significantly prolonged. Thus, the present inventors for the first time discovered that administration of anti-IL-6 receptor antibodies could suppress cytotoxic T cell induction and thereby suppress acute rejection after transplantation.

The present invention discloses Lactobacillus fermentum HY01 with effects of intestinal tract function regulation and colitis prevention, and uses thereof, wherein the preservation number of the Lactobacillus fermentum HY01 is CCTCCM2015792. According to the present invention, the in vitro tolerance of the Lactobacillus fermentum HY01 is strong, wherein the survival rate of the Lactobacillus fermentum HY01 is 103.73+ / -8.60% after the Lactobacillus fermentum HY01 is treated for 3 h in the artificial gastric juice with the pH value of 3.0, the Lactobacillus fermentum HY01 can grow at the bile salt concentration of 0.3%, the growth efficiency is 21.62+ / -0.86% of the growth efficiency of the bile salt-free culture, and the Lactobacillus fermentum HY01 has good in vitro tolerance; and the in vivo mouse test results show that the Lactobacillus fermentum HY01 can alleviate the colonic shortening and the colonic edema of the colitis mice, and the inflammatory cell infiltration and the mucosal injury in colon, such that the Lactobacillus fermentum HY01 has the colitis prevention effect.

The invention belongs to the field of animal experiment models, and discloses application of a composite high-fat forage to construct a non-alcoholic fatty liver disease rat model. The high-fat forage is composed of the following raw materials in percent by mass: 77.5% of a rat basic forage, 10% of egg, 10% of coconut oil, 2% of cholesterol, 0.5% of bile salt, and 500mg / kg / d of sodium valproate calculated according to the rat weight. After 8 weeks, rats all have typical non-alcoholic fatty live symptoms, and liver has a lot of fat accumulation along with inflammatory cell infiltration. The model establishing time is short, the success rate is high, and the composite high-fat forage is applicable to pathogenesis research induced by high-fat-diet combined medicines with liver-toxicity side effect, screening of related control measures and efficacy evaluation of treatment medicines.

The invention relates to bifidobacterium longum capable of relieving atopic dermatitis and application thereof, and belongs to the technical field of microorganisms and the technical field of medicine. Bifidobacterium longum has the effect of relieving atopic dermatitis, and has the advantages that the ear swelling degree of a mouse with atopic dermatitis is remarkably decreased; dermal pathologysymptoms of the mouse with atopic dermatitis are relieved remarkably, and inflammatory cell infiltration is relieved; the serum IgE of the mouse with atopic dermatitis is reduced remarkably; the levelof IL-4 and IL-13 in skin tissue of the mouse with atopic dermatitis is decreased remarkably; the level of histamine in the skin tissue of the mouse with atopic dermatitis is decreased remarkably. Inthis way, bifidobacterium longum has broad application prospects in preparation of products for preventing and / or treating atopic dermatitis.

The invention relates to a clinic detection marker of an inflammatory bowel disease, and applications thereof, and concretely relates to a molecular marker-Erbin gene in the inflammatory bowel disease, and an application of an inhibitor chloroquine of a downstream autophagy pathway regulated by the marker. An experiment result shows that the intestinal mucosa damage of DSS induced Erbin<+ / +> and Erbin<- / -> mice injected with chloroquine are substantially reduced, the intestinal mucosa damage of the Erbin<- / -> mice is obviously severer than that of the Erbin<+ / +> mice, and the mice injected with chloroquine have higher intestinal mucosa integrity, substantially lower inflammatory cell infiltration and substantially alleviated inflammatory bowel disease symptoms than mice not injected with the chloroquine, so the autophagy inhibitor chloroquine can improve the integrity of the intestinal mucosa and has a very good IBD inhibition effect, thereby the chloroquine has certain prevention and treatment effects on the inflammatory bowel disease.

The invention belongs to the traditional medicine technical field, which relates to a traditional Chinese medicine composition for curing early and intermediate chronic renal failure. Under the guidance of a traditional Chinese medicine theory that 'interior accumulation is blood stasis' and 'chronic diseases transforming to collaterals is blood stasis', with the treatment principle of differentiation of symptoms and sighs, differentiation of channels, and based on the principle of strengthening body resistance and reducing turbidity, promoting blood circulation and removing blood stasis, the invention adopts traditional medicine such as lanceolata, epicedium, salvia miltiorrhizae, prepared rhubarb, perilla, peach kernel and the like, which are made into the compositions. Confirmed by clinical and animal experiments, the invention has the renal protecting functions of improving clinical symptoms of patients with early and intermediate chronic renal failure, reducing retention of metabolites of bodies, improving anemia, adjusting lipid and calcium-phosphorus metabolism, reducing the expression of fibrosis factors in nephridial tissues, preventing and treating glomerulosclerosis, lightening renal tubule damage and renal interstitial inflammatory cell infiltration and delaying renal fibrosis. The invention has the advantages of safety, efficiency and low cost, which is applied to the long-term medication for patients with early and intermediate chronic renal failure.

The invention belongs to the fields of medical evaluation, detection technology and experimental zoology, and specifically relates to a construction method of animal model of rat which is used for screening medicaments for treating chronic inflammation, and evaluating methods for treating systematic chronic inflammation. The method comprises the following step that healthy male SD rats are administered with lipopolysaccharide by tail intravenous injection, on an every first day of a week for 4-8 weeks persistently, at a dosage of 120-300 [mu]g per kg of body weight, so that pathologic changes, which meet pathological characteristics of chronic inflammation, mainly of an increased ratio of peripheral blood leucocyte count to neutrophile granulocyte, an increased serum hypersensitive C-creative protein level, infiltration of heart, liver, lung, kidney in inflammatory cells, and haemostasis and oedema of tissues are generated. The method has a good repeatability, and operation of the method is simple, easily controllable and mechanism-clear, besides indexes can be analyzed quantitatively and are convenient for statistics treatments. In addition, the constructed animal model is more ideal and more conform to clinic pathological and physiological changes of the type of disease.

Evidence is presented that inflammation and injury involves activation of xanthine oxidoreductase (XOR) in the newly recruited mononuclear phagocytes (MNP). XOR has been shown to be increased predominantly in the MNP that increase rapidly in the lungs of rats that develop acute lung injury (ALI) following intratracheal cytokine insufflation. XOR was recovered from the MNP largely converted to its oxygen radical generating, reversible O-form, and alveolar MNP exhibited increased oxidative stress as evidenced by increased nitrotyrosine staining. Cytokine insufflation also increased alveolar cell apoptosis. A functional role for XOR in cytokine induced inflammation was demonstrated. Tungsten and allopurinol decreased MNP XOR induction, nitrotyrosine staining, inflammatory cell infiltration, and alveolar cell apoptosis. Transfer of control or allopurinol treated MNP into rat lungs and confirmed a specific role for MNP XOR in promoting lung inflammation. These data indicate that XOR can contribute to lung inflammation by its expression and conversion in a highly mobile inflammatory cell population.

The invention relates to application of colchicin in preparing drugs, in particular to application of colchicin in pharmacotherapy of cholestatic liver disease, the application of colchicin in preparing a cholestatic liver disease drug, and the application of colchicin in preparing the drug for treating gestation intrahepatic cholestasis syndrome, inner primary cirrhose biliaire, primary sclerosing cholangitis severe jaundice or immunity jaundice cholestatic liver disease. The colchicin can effectively lower liver injury and cholestasis caused by cholestatic liver disease, i.e. the colchicin can effectively treat cholestatic liver disease. The colchicin can effectively lighten hepatic cell necrosis, inflammatory cell infiltration and bile capillary hyperplasia caused by cholestasis. The colchicin can effectively increase bile acid, bilirubin and expression of phospholipid transporters BSEP, MRP2 and MDR3 in a bile duct, accelerates excretion of bile acid, bilirubin and phospholipid deposited in the body and reduces liver damage.

Compositions and methods for treating inflammatory cell infiltration in a tissue of a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1 / immunosuppressant combination admixed with a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods of the present invention are useful for treating numerous inflammatory based diseases and injuries.

The invention belongs to the technical field of traditional Chinese medicines and relates to oral liquid for treating chronic atrophic gastritis. The oral liquid is prepared by the following components in parts by weight: 10 parts of Zhejiang white atractylodes rhizome, 15 parts of poria cocos, 10 parts of orange peel, 10 parts of pinellia tenata breit, 10 parts of vinegar rhizoma cyperi, 10 parts of fructus amomi, 10 parts of mangnolia officinalis, 10 parts of vinegar curcuma aromatic, 15 parts of artemisia anomala, 6 parts of cassia twig, 10 parts of rhizoma corydalis, 10 parts of hawthorn, 10 parts of roasted malt, 10 parts of roasted medicated leaven, 10 parts of lindera aggregate, 15 parts of radix paeoniae alba, 12 parts of radix pseudostellariae and 3 parts of liquorice. The oral liquid provided by the invention has the effects of relieving inflammatory cell infiltration, regulating cellular immunity and humoral immunity function, restraining the activity of pepsinogen to promote proliferation and recovery thereof, strengthening barrier protection function of the mucosa, regulating gastrointestinal motility, increasing permeability of gastric mucosa, improving blood circulation of the mucosa, promoting atrophic glands to recover, and delaying or reversing progression of diseases.

The invention belongs to the field of medicine and specifically relates to novel application of isoliquiritigenin, more specifically to application of isoliquiritigenin in preparation of drugs used for improving and treating psoriasis, drugs used for improving or treating parakeratosis, hyperkeratosis, acanthosis and inflammatory cell infiltration, drugs used for inhibiting the expression levels of NF-kB and p-NF-kB, and drugs used for improving or treating autoimmune diseases.

The invention discloses a method for establishing an in-vitro model capable of simulating barrier functions of pulmonary epithelial cells and capillary endothelial cells during acute lung injury. Themethod comprises the following steps: (1) inoculating endotoxin-infected mouse C3H / 10T1 / 2 microvascular endothelial cell strains into lower culture of a cell by using a Transwell co-culture system; inoculating mouse-derived TC-1 pulmonary epithelial cells into the upper layer of the cell, co-culturing for a period of time, and collecting the cell culture supernatant; and (2) detecting conditions of barrier synthesis of pulmonary epithelial cells / capillary endothelial cells in the cell culture supernatant and expressions of inflammatory factor and inflammatory cell infiltration associated proteins, and establishing a pulmonary epithelial cell / capillary endothelial cell co-culture model applicable to endotoxic acute lung injury study. The model established by the method disclosed by the invention is close to a cell barrier function during in-vivo endotoxic acute lung injury, and can provide a reliable model basis for clinical acute lung injury study.

The invention belongs to the technical field of new indications of drugs, and particularly discloses an application of externally used skin generation oil in preparation of drugs for preventing or treating diabetic peripheral circulation disturbance and foot ulcer. The externally used skin generation oil can effectively improve low temperature at soles due to peripheral circulation disturbance in early stage of diabetic foot ulcer, recover the sole pain threshold to a normal level, accelerate diabetic foot ulcer wound repair and shorten the wound repair time. The area of a foot ulcer wound surface of a diabetic rat is reduced to (4.0 plus or minus 0.1 mm<2>) from (51.3 plus or minus 3.5 mm<2>) after treated with the skin generation oil for 35 days, the wound surface heals basically, the skin is red and dry, and the skin surface is smooth; HE (hematoxylin-eosin) dyeing results show that the skin tissue structures of the foot wound surfaces of rats in an externally used skin generation oil group and an externally used skin generation oil and metformin group is relatively complete, collagen fibers at the wound edge are arranged in order, and inflammatory cell infiltration of wound surface tissue is reduced obviously.

The invention discloses application of p-hydroxybenzoic acid in preparing a drug for treating an inflammatory bowel disease. At a dose significantly lower than mesalazine, the p-hydroxybenzoic acid can significantly inhibit the increase in disease activity index scores of enteritis model mice induced by dextran sodium sulfate, improve colon length shortening of the colitis model mice, reduce the colonic MPO activity of the mice, and reduce the inflammatory cell infiltration of colon tissues in the colitis model mice. According to the application, the p-hydroxybenzoic acid can alleviate the inflammatory reaction of the DSS-induced inflammatory bowel disease model mice and improve the severity of the inflammatory bowel disease, and can be used for preparing the drug or a health care productfor treating the inflammatory bowel disease.

The invention relates to application of sanguisorba total saponin to treatment of inflammatory bowel diseases, relates to a treatment effect of sanguisorba total saponin on inflammatory bowel diseases, belongs to the pharmaceutical field and provides application of sanguisorba total saponin to significant reversal of colon injury caused by TNBS. Experiments prove that sanguisorba saponin can obviously reduce the phenomenon that the weight of rats induced by TNBS and suffered from colitis is reduced and also can obviously reduce the degree of pathological changes of the colitis of the rats induced by TNBS; inflammatory cell infiltration is reduced; the mucosal epithelial degeneration is reduced; TNBS causes severe inflammation response in the rats and also causes increase of expression of proinflammatory factors including TNF-alpha, IL-1beta and IL-6 in serum of the rats; sanguisorba saponin can reverse the phenomenon that the inflammatory factors in the serum of the rats are increased; TNBS simultaneously causes increase of expression of MPO and MDA and reduction of expression of SOD in colon oxygen free radical systems of the rats; therefore, sanguisorba saponin can reverse the phenomenon that the colon oxygen free radical systems of the rats are disordered. The invention further provides influence of sanguisorba saponin on inflammatory factors in LPS-excited RAW 264.7 macrophages; results show that sanguisorba saponin can significantly reduce expression of TNF-alpha, IL-6 and IL-1beta, so that the anti-inflammatory effect is achieved; sanguisorba total saponin can be applied to treatment of inflammatory bowel diseases.

The invention belongs to the technical field of pharmacy. According to the application of a protein tyrosine phosphatase SHP2 inhibitor SHP099 in preparation of the medicine for treating psoriasis, aiming at an imiquimod-induced mouse psoriasis-like disease model, the SHP099 can effectively improve epidermal thickening of mouse skin lesion tissues, inflammatory cell infiltration and the level of inflammatory factors in mouse serum. At the cellular level, the SHP099 can significantly reduce the release of inflammatory factors related to psoriasis.

The invention provides a method and composition for regulating and controlling autoimmune diseases through a polyamine compound. The invention provides macrophages treated by a polyamine compound, a corresponding cellular preparation and a composition for up-regulation of an internal arginase level or down-regulation of an internal arginase level. The preparation and composition can be used for treating multiple sclerosis, significantly reduces inflammatory cell infiltration, inhibits inflammatory response through down-regulation of a proinflammatory cytokine level, reduces inflammatory cell infiltration and a demyelination degree of the central nervous system and reduces the incidence of multiple sclerosis and pathogenetic conditions.

The invention discloses application of cobra venom in preparation of a medicament for treating lung inflammatory disease and pulmonary fibrosis. Animal experiment proves that Chinese cobra venom can alleviate acute endotoxin poisoning symptom within a range of 10-3000mug / kg, particularly has obvious therapeutic action on lung inflammatory disease caused by endotoxin, and can be used for alleviating inflammatory cell infiltration, alveolar septum thickening, and focal atelectasis and emphysema. Repeated small dose of endotoxin can result in pulmonary fibrosis, the cobra venom can significantly alleviate pulmonary fibrosis symptom and reduce alveoli damage and collagen hyperplasia. Naturally-modified Chinese cobra venom and physically-modified Chinese cobra venom have similar actions, but the physically-modified Chinese cobra venom has better action. Used for treating lung inflammatory disease, the Chinese cobra venom has the advantages of low dose, safety, capability of being orally administrated, injected, and administered through oral mucous membrane and skin and the like.

The invention belongs to the fields of genetic engineering and pharmacy, and discloses a TGF-R (Transforming Growth Factor-Receptor) antisense sequence and an application thereof in preparing a medicament for preventing airway inflammation reaction. The nucleotide sequence of the TGF-R antisense sequence is as shown in SEQ ID NO.1. Due to adoption of the antisense sequence, the airway inflammatory cell infiltration is remarkably alleviated, and thus the TGF-R antisense sequence can be applied to preparation of medicaments for preventing airway inflammation reaction.

The invention provides a medicine for treating periodontal ligament cell dysfunction and alveolar bone loss caused by periodontal pathogen infection. The medicine includes an IL-18 antibody and / or anIL-18R receptor siRNA exosomes. The medicine of the present invention uses the IL-18 antibody and / or the IL-18R receptor siRNA exosomes as a functional component, by combining with IL-18 in periodontal tissue, the secretion of proinflammatory cytokines by periodontal ligament cells can be inhibited, the periodontal ligament cell loss and inflammatory cell infiltration caused by periodontal ligament cell dysfunction under inflammation can be improved, the occurrence and development of periodontal disease can be prevented, and the medicine has potential application value for the clinical prevention and treatment of periodontal disease.

The invention discloses bacteroides fragilis capable of regulating and controlling relative abundance of akkermansia in intestinal tracts, and belongs to the technical field of microorganisms. The bacteroides fragilis CCFM1123 is screened out, and the bacteroides fragilis CCFM1123 has the effect of relieving inflammation. Specifically, the relative abundance of lactobacillus and akkermansia in theintestinal tract of an inflammatory mouse is remarkably improved; the content of proinflammatory factors TNF-alpha and IL-6 in the serum of the inflammatory mouse is remarkably reduced; intestinal inflammatory cell infiltration and mucosal bleeding caused by inflammatory response of the inflammatory mouse are remarkably reduced; and production of short-chain fatty acids in the intestinal tract ofthe inflammatory mice is obviously promoted. Therefore, the bacteroides fragilis CCFM1123 has a huge application prospect in preparation of products (such as foods or medicines) for preventing and / ortreating inflammation.

The invention discloses an application of Dendrobium nobile total alkaloids in the preparation of medicines for preventing or treating acute and chronic liver injury diseases. The Dendrobium nobile total alkaloids have prevention and treatment effects on CCL4, alcohol or D-galactose induced acute liver injuries and CCL4 induced chronic liver injuries. The Dendrobium nobile total alkaloids are used to obviously reduce the activity of ALT and AST in serum, substantially reduce the content of MDA in liver homogenate and improve the expression of Nrf2, Nqo1 and Ho-1mRNA. A result of liver tissue slice observation shows that after the Dendrobium nobile total alkaloids are used, the liver tissue lesion necrosis disappears, the liver lobule structure is basically complete, and the inflammatory cell infiltration is obviously mitigated.

The invention provides medicine for treating asthma. The medicine is glycoprotein, mixture of polysaccharide and protein, polypeptide or protein. The medicine has the advantages that the bronchial hyperresponsiveness of a mouse asthma model can be effectively lowered, the tracheospasm can be relieved, and airway pressure-time index (APTI) is 726-880 per second centimeter water column; the inflammation in the lung can be treated effectively, inflammatory cell infiltration can be reduced, and the percentage of eosinophilic granulocyte is 14.6-16.6%; the gamma-interferon (IFN-gamma) and antibody which are capable of inhibiting asthmatic attack can be increased, and the contents of interleukin-4 (IL-4), interleukin-5 (IL-5) and interleukin-13 (IL-13) which can induce the asthma can be lowered; the medicine is safe, efficient, free of side effect, quick in action during asthma preventing and treatment, capable of relieving chest distress and short of breath and evident in curative effect on the asthma.

The invention discloses applications of vorinostat in aspect of drugs for treating autoimmune diseases. The experiment result disclosed by the invention shows that due to the vorinostat, the morbidity of the experimental autoimmune encephalomyelitis of mice is reudced, and also the average score, the highest score and the total score of clinical marks are reduced; spinal cord inflammatory cell infiltration and spinal cord demyelination can be alleviated; the weight percent of a cell Th1 related to IFN (Interferon)-gamma secretion and a cell Th17 cell related to IL-17A secretion accounting for positive T cells CD4 in the spleen can be reduced. Therefore the invention relates to the preparation of the drug for inhibiting the experimental autoimmune encephalomyelitis of an animal model, and the drug is expected to treat the diseases related to multiple sclerosis, ophthalmoneuromyelitis, acute disseminated encephalomyelitis and the like.

The invention relates to black cumin seed oil nose drop and a preparation method thereof. The black cumin seed oil nose drop is prepared from black cumin seed oil or from black cumin seed oil, scabrous mosla herb, herba ephedra, radix angelicae, violet magnolia, centipeda minima, schizonepeta and radices sileris in a compounding manner. The black cumin seed oil nose drop disclosed by the invention is used for directly acting on the mucosa of the nasal cavity, becomes effective rapidly, and can relieve inflammatory cell infiltration of the nasal mucosa caused by rhinitis and nasosinusitis and inhibit hyperplasia of connective tissues below the mucosa so as to improve nasal obstruction caused by swelling of the nasal mucosa, so the black cumin seed oil nose drop is suitable for treating various rhinitis and has a better effect than clinical commonly-used biyanling pills, centipeda minima nasal drops and the like.

The invention discloses application of melbine in preparing medicines for relieving cisplatin-induced acute kidney injury related diseases, and discloses application of melbine in new indication. The melbine disclosed by the invention can be used for relieving cisplatin-induced acute kidney injury related diseases which include acute kidney injury renal function, apoptosis of renal tubular cell, renal inflammatory cell infiltration and like diseases; and acute kidney injury is relieved by inhibiting the apoptosis of renal tubular cell mainly by improving the autophagy level of the renal tubular cell.

The invention relates to a new application of a monomer compound CDCA, and particularly relates to the application of the CDCA in preparation of a drug for treating osteoarthritis and a drug composition for treating the osteoarthritis. The drug composition can be prepared into an injection, a tablet, a capsule, an electuary, a drop, a granule or an ointment by adding general medicinal auxiliary components to the CDCA being not less than 98% in purity. A pharmacological experiment result proves that the CDCA can significantly improve inflammatory cell infiltration, proliferation of fibrous tissue and cartilage surface damage and the like situations in an osteoarthritic location, can reduce the levels of MMP-1, MMP-3, IL-1[beta] and PGE2 in synovial fluid and has a strong osteoarthritis-resistant effect, so that the CDCA can be used for preparing a drug for treating the osteoarthritis. The invention provides a new drug source to treatment of the osteoarthritis.

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to an oral skin regeneration promoting oil for treating oral cavity burn and scald and a preparation method and application thereof. The oral skin regeneration promoting oil is prepared from, by weight, 10-30 parts of scutellaria baicalensis, 10-30 parts of coptis chinensis, 10-30 parts of amurcork tree bark, 10-30 parts of Chinese rhubarb, 10-30 parts of astragali radix, 10-30 parts of angelica sinensis, 10-30 parts of garden burnet, 10-30 parts of rehmannia glutinosa, 10-30 parts of angelica dahurica,10-30 parts of blackend swallowwort root, 10-30 parts of bletilla striata, 10-30 parts of frankincense, 10-30 parts of myrrh, 3-8 parts of borneol and 1000-1500 parts of edible vegetableoil, wherein the skin regeneration promoting oil is prepared by heating and mixing the materials in batches. Staining results show that the inflammatory cell infiltration of wound tissues of oral cavity burn and scald site of a rat group using the skin regeneration promoting oil is obviously reduced, the tissue structure is relatively complete, the skin regeneration promoting oil has the effectsof treating oral cavity burn and scald caused by boiling water, acid and alkali. The oral toxicity experiment of the skin regeneration promoting oil show that there is no significant difference in body weight, liver and kidney function of rats compared with a blank group, and no obvious influence is produced.